AAM Applauds CMS For Biosimilar Substitution Flexibility In Medicare Part D Plans
The Final Rule Will Come Into Effect In CY2025
Despite receiving mixed opinions on the Medicare Part D final rule, CMS sees support from the off-patent group AAM, which said that the new policy will have an “immediate impact” on cost reduction and increased access to biosimilars.
